45.21
3.93%
+1.71
アフターアワーズ:
45.21
Soleno Therapeutics Inc (SLNO) 最新ニュース
Soleno Therapeutics Stands with the Prader-Willi Syndrome Community
GlobeNewswire Inc.
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock
GlobeNewswire Inc.
Soleno Therapeutics Announces Proposed Public Offering of Common Stock
GlobeNewswire Inc.
US Stocks Kick Off The Week In The Green, Tesla Rockets On China's FSD Approval, Yen Rallies: What's Driving Markets Monday?
Benzinga
Why Soleno Therapeutics Stock Is Skyrocketing Today
The Motley Fool
Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)
GlobeNewswire Inc.
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
GlobeNewswire Inc.
Soleno Therapeutics, Inc. (SLNO) Is a Great Choice for 'Trend' Investors, Here's Why
Zacks Investment Research
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Here's Why Momentum in Soleno Therapeutics, Inc. (SLNO) Should Keep going
Zacks Investment Research
Here's What Could Help Soleno Therapeutics, Inc. (SLNO) Maintain Its Recent Price Strength
Zacks Investment Research
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Forget The Magnificent 7: Did Anyone Back These 1,000% Gainers In 2023?
Benzinga
The best-performing stock of the year rose nearly 10-fold, while the 2nd-best averted disaster to surge 1,000% in a wild 2023
MarketWatch
The best-performing stock of the year rose nearly 10-fold, while the 2nd-best averted disaster to surge 1,000% in a wild 2023
MarketWatch
The best-performing stock of the year rose nearly 10-fold, while the 2nd-best averted disaster to surge 1,000% in a wild 2023
MarketWatch
The best-performing stock of the year rose nearly 10-fold, while the 2nd-best averted disaster to surge 1,000% in a wild 2023
MarketWatch
Why Soleno Therapeutics Stock Ticked Higher on Thursday
The Motley Fool
4 Analysts Have This to Say About Soleno Therapeutics
Benzinga
大文字化:
|
ボリューム (24 時間):